Insulet Partners with Calm to Bring Mindfulness and Well-Being Tools to the Diabetes Community, Featuring a New Sleep Story Narrated by Lila Moss Business Wire The partnership introduces The Mind in Range Collection, a set of tailored mindfulness resources available at no cost to the diabetes community, including a meditation series, a breathing exercise, and a new Calm Sleep Story narrated by Omnipod® user and fashion model Lila Moss, designed to help listeners unwind and feel supported With 359 million people worldwide living with an anxiety disorder1, and people with diabetes being 20% more likely to develop anxiety2, this initiative reinforces Insulet’s commitment to whole-person care and positions mental health as essential to diabetes management The integrated content collaboration is the first-of-its-kind between Calm and a MedTech company, built on Insulet's global research showing the essential role emotional well-being plays in diabetes management
Xsolla Connect Returns to Brighton Business Wire Connecting The UK Game Development Community For Networking And Insights During Develop:Brighton
Cloudflare Introduces Precursor; One-Click Behavioral Defense Against Modern Bots Business Wire Built on one of the world’s largest networks, Precursor is the only defense of its kind to replace disruptive checkpoints to stop evasive bots without slowing down users
Tenpoint Therapeutics Announces United Kingdom Submission of Marketing Authorization Application to the Medicines and Healthcare Products Regulatory Agency (MHRA) for the Treatment of Blurry Close-Up Vision (Presbyopia) in Adults July 13, 2026 The product, branded YUVEZZI™, received approval from the U.S. Food and Drug Administration (FDA) in January 2026 as the first and only dual-agent (combination) eye drop approved for the treatment of presbyopia in adults The United Kingdom submission is an important milestone for Tenpoint Therapeutics’ continued global expansion strategy
Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis July 13, 2026 — First Long-Term Study of an Orexin 2 Receptor Agonist to Demonstrate Sustained Clinically Meaningful Improvements in Wakefulness and Excessive Daytime Sleepiness for Up to Nine Months in Narcolepsy Type 1 and Type 2 — — Improvements in Patient-Reported Cognition and Fatigue Were Also Sustained — — Alixorexton Was Generally Well Tolerated at All Doses Tested —
Fastmail Launches EU-Hosted Email Infrastructure, Giving Customers Control Over Where Their Data Lives July 13, 2026 Amsterdam data centre brings EU hosting to customers seeking simpler compliance and faster service
PropertyStream and Offr Launch TRANSACT as UK Homebuying Enters the Digital Era July 13, 2026 The new partnership combines award-winning estate agency websites with end-to-end transaction technology to help real estate agents prepare for the future of digital home buying.
Fresha Explores The Future of AI in Couture and Selfcare with Iris van Herpen Backstage at Paris Haute Couture Week July 10, 2026 Fresha, the world’s leading AI-powered beauty and wellness booking platform, joined the hair team backstage at Paris Haute Couture Week this week to power Fresha Ambassador and internationally renowned hairstylist Hester Wernert-Rijn as she led the hair for Iris van Herpen’s Autumn/Winter 2026 Haute Couture collection, Sonic Starquakes. Following the runway presentation, Fresha secured an [...]
U.K. Firms Make Cyber Resilience Measurable July 10, 2026 Boards and regulators push enterprises to prove response readiness and operational impact as AI-enabled threats grow, ISG Provider Lens® report says
e.l.f. Cosmetics is Giving Away Thousands of Driving Lessons to UK Learners July 9, 2026 e.l.f. launches “Grip, Set, Go,” in partnership with RED Driver Training, democratising access to a skill that lasts a lifetime.